Is the GSK share price the bargain of the year?

Plans for a break-up could be just what the doctor ordered for pharma group GlaxoSmithKline plc (LON:GSK), says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharma giant GlaxoSmithKline (LSE: GSK) is heading for a break-up. Chief executive Emma Walmsley will oversee the creation of two companies — a focused and faster-growing pharmaceutical company and a profitable, stable consumer healthcare business.

This strategy isn’t a sure thing, but I think there’s a good chance it will work. Today I’ll explain why. I’ll also take a look a FTSE 250 stock which I think offers an interesting mix of opportunity and risk.

A break-up makes sense

In the past I’ve been a supporter of Glaxo’s conglomerate structure. This combines mature consumer products such as Panadol, Nicorette and Sensodyne with cancer treatments and other pharmaceuticals.

But this hasn’t worked out well. The group’s performance has stagnated for years and its shares have lagged the FTSE 100. In the meantime, debt levels have risen.

After less than two years in the job, Ms Walmsley has secured a deal to merge the firm’s consumer healthcare business with that of US pharma rival Pfizer. The resulting joint venture is expected to become a standalone business within three years.

One big advantage for Glaxo shareholders is that a sizeable part of the group’s £22bn net debt is likely to be carved out into the new consumer business. This will leave the pharmaceutical business with a stronger balance sheet and more flexibility to invest in new growth opportunities.

Too good to be true?

You could argue that this is all just financial engineering, designed to disguise the fact that Glaxo has too much debt and is due for a dividend cut.

The reality is that we won’t know how well the split will work for another few years.

In the meantime, I’m happy to give Ms Walmsley the benefit of the doubt. Although I don’t think that GlaxoSmithKline is the bargain of the year, I do think that the group’s 5.3% dividend yield remains attractive for income investors.

How will this story end?

FTSE 250 cinema chain Cineworld Group (LSE: CINE) has been one of the stock market success stories of recent years. The firm’s shares have risen by 118% in five years and are up by 6% at the time of writing.

The twist in this story is that Cineworld splashed out $5.8bn on the acquisition of US rival Regal Entertainment last year. This has transformed the UK firm into the second-largest cinema chain in the world.

Results published today show that the combined group’s revenue rose by 7.2% to $4,711m last year, while its adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) rose by 9.4% to $1,0722m. Both figures are calculated as though the two companies had always been combined.

This ambitious acquisition is expected to generate cost savings of $150m in 2019. But this deal has also left Cineworld with net debts totalling $3.9bn. That’s equivalent to about 3.7 times adjusted EBITDA. That’s well above my preferred maximum of 2x EBITDA.

Today’s numbers suggest to me that reducing debt to a more comfortable level could take three to five years. In my view, a dividend cut would be prudent to speed up this process. Instead, the 2018 payout will be lifted by 15%.

Cineworld shares now trade on about 12.5 times 2019 earnings, with a forecast yield of 4.6%. Given the group’s debt level, I’d say the shares look fully valued. I’d hold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »